UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Driving with a neurodegenerative disorder: an overview of the current literature

Journal of neurology, 2017-08, Vol.264 (8), p.1678-1696

2017

Volltextzugriff (PDF)

The visual cortex and visual cognition in Huntington’s disease: An overview of current literature

Behavioural brain research, 2018-10, Vol.351, p.63-74

2018

Volltextzugriff (PDF)

Cost-effectiveness of LiveLighter® - a mass media public education campaign for obesity prevention

PloS one, 2022-09, Vol.17 (9), p.e0274917-e0274917

2022

Volltextzugriff (PDF)

A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation

Alzheimer's research & therapy, 2021-07, Vol.13 (1), p.1-132, Article 132

2021

Volltextzugriff (PDF)

Cognitive Performance and Apathy Predict Unemployment in Huntington’s Disease Mutation Carriers

The journal of neuropsychiatry and clinical neurosciences, 2018-07, Vol.30 (3), p.188-193

2018

Volltextzugriff (PDF)

An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds

Clinical neurophysiology, 2018-11, Vol.129 (11), p.2325-2332

2018

Volltextzugriff (PDF)

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M 1 -receptor partial agonist for the treatment of dementias

British journal of clinical pharmacology, 2021-07, Vol.87 (7), p.2945-2955

2021

Volltextzugriff (PDF)

First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias

British journal of clinical pharmacology, 2021-07, Vol.87 (7), p.2945-2955

2021

Volltextzugriff (PDF)

The relationship between alcohol consumption and related harm among young university students

Health promotion journal of Australia, 2016-04, Vol.27 (1), p.15-20

2016

Volltextzugriff (PDF)

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease

Journal of neurology, neurosurgery and psychiatry, 2012-07, Vol.83 (7), p.687-694

2012

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial

British journal of clinical pharmacology, 2021-11, Vol.87 (11), p.4439-4449

2021

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 -acetylcholine receptor agonist: A randomized cross-over trial

British journal of clinical pharmacology, 2021-11, Vol.87 (11), p.4439-4449

2021

Volltextzugriff (PDF)

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

Alzheimer's research & therapy, 2021-04, Vol.13 (1), p.1-19, Article 87

2021

Volltextzugriff (PDF)

Reliability and Factor Structure of the Short Problem Behaviors Assessment for Huntington’s Disease (PBA-s) in the TRACK-HD and REGISTRY studies

The journal of neuropsychiatry and clinical neurosciences, 2015, Vol.27 (1), p.59-64

2015

Volltextzugriff (PDF)

Reversal of mecamylamine‐induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.888-899

2018

Volltextzugriff (PDF)

MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1

Brain (London, England : 1878), 2019-07, Vol.142 (7), p.1876-1886

2019

Volltextzugriff (PDF)

Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease

Psychiatry research, 2013-05, Vol.207 (1), p.118-126

2013

Volltextzugriff (PDF)

Predictors of simulated driving performance in Huntington's disease

Parkinsonism & related disorders, 2019-03, Vol.60, p.64-69

2019

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine

Alzheimer's & dementia : translational research & clinical interventions, 2020, Vol.6 (1), p.e12093-n/a

2020

Volltextzugriff (PDF)

Longitudinal resting state fMRI analysis in healthy controls and premanifest Huntington's disease gene carriers: A three-year follow-up study

Human brain mapping, 2015-01, Vol.36 (1), p.110-119

2015

Volltextzugriff (PDF)

Comparable rates of simulator sickness in Huntington’s disease and healthy individuals

Transportation research. Part F, Traffic psychology and behaviour, 2019-01, Vol.60, p.499-504

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation

Journal of psychopharmacology (Oxford), 2017-02, Vol.31 (2), p.192-203

2017

Volltextzugriff (PDF)

A cross sectional evaluation of a total smoking ban at a large Australian university

BMC research notes, 2016-05, Vol.9 (285), p.288-288, Article 288

2016

Volltextzugriff (PDF)

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Journal of visualized experiments, 2019-02 (144)

2019

Volltextzugriff (PDF)

Elevated brain iron is independent from atrophy in Huntington's Disease

NeuroImage (Orlando, Fla.), 2012-07, Vol.61 (3), p.558-564

2012

Volltextzugriff (PDF)

1 – 25 von 421

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(342)
Mit Volltextzugriff
(326)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(420)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Driving with a neurodegenerative disorder: an overview of the current literature

The visual cortex and visual cognition in Huntington’s disease: An overview of current literature

Cost-effectiveness of LiveLighter® - a mass media public education campaign for obesity prevention

A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation

Cognitive Performance and Apathy Predict Unemployment in Huntington’s Disease Mutation Carriers

An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M 1 -receptor partial agonist for the treatment of dementias

First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias

The relationship between alcohol consumption and related harm among young university students

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 -acetylcholine receptor agonist: A randomized cross-over trial

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

Reliability and Factor Structure of the Short Problem Behaviors Assessment for Huntington’s Disease (PBA-s) in the TRACK-HD and REGISTRY studies

Reversal of mecamylamine‐induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses

MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1

Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease

Predictors of simulated driving performance in Huntington's disease

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine

Longitudinal resting state fMRI analysis in healthy controls and premanifest Huntington's disease gene carriers: A three-year follow-up study

Comparable rates of simulator sickness in Huntington’s disease and healthy individuals

Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation

A cross sectional evaluation of a total smoking ban at a large Australian university

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Elevated brain iron is independent from atrophy in Huntington's Disease

Suchergebnisse filtern